Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From ImmuPharma PLC

Interview: Double Delight For ImmuPharma's Dimitriou

It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.

Business Strategies Leadership

ImmuPharma Soars On Avion Lupus Deal

US speciality drugs group will fund the $25m costs of the UK company's new Phase III trial of Lupuzor, which has been much maligned by analysts.

Strategy Financing

ImmuPharma Still Upbeat About Lupuzor But Market Unconvinced

The UK biotech is expanding access to its unapproved lupus drug, has signed a licensing deal with Incantera and unveiled plans to divest its metabolic disorder subsidiary Ureka but fears about ImmuPharma's future remain.

Immune Disorders Clinical Trials

Pipeline Watch: Phase III Progress With Semaglutide, Tecentriq And Epidaza

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Elro Pharma Sarl
    • Ureka Sarl
UsernamePublicRestriction

Register